Please assess the completion status of the following clinical trial:

Trial Title: Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with pulmonary infection due to COVID-19, admitted in ICU and require mechanical ventilation or ECMO~* Male and female with Age\>18 years old~* Signed informed consent from patient or relatives~Exclusion Criteria:~* Pregnant or breast-feeding women~* Severe systemic disease (cancer, auto-immune etc) before infection accompanied by reduced life expectancy \<6 months~* Participation in another trial of an investigational drug or device~* Corticosteroid Use before initiation of treatment~* Sympathomimetic Use before initiation of treatment (epinephrine, norepinephrine, dobutamine, dopamine, phenylephrine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T3 solution for injection (Type: EXPERIMENTAL): T3 Solution for injection 10 μg/ml, each vial contains 150μg of liothyronine in a total volume of 15ml. The dose administered will be 0.8g/kg i.v. bolus starting within 60min after respiratory support and will be followed by an infusion of 0.113g. kg-1.h-1 i.v. for 48 hours (therapeutic dose). After the first 48h, a maintenance dose will be administered corresponding to 50% of the therapeutic dose (0.057g. kg-1.h-1 i.v.). Drug administration will stop after successful weaning or end of followup (maximum 30 days).
- Placebo (Type: PLACEBO_COMPARATOR): Composition identical apart from the active substance. Same dosage.

Based on this trial design, predict the completion outcome and termination type (if applicable).